Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 49, inclusive at the time of enrolment~* in good health as determined by the outcome of medical history, physical examination screening/baseline labs and clinical judgment of the investigator~* Male~* Must have received polio vaccinations with OPV according to the Polish National Immunization Program as a child based on vaccination cards or information given by subjects during interview with investigator~* Preferred: number (and date) of polio vaccinations known~* Willingness and ability to adhere to the study regimen~* Having a signed informed consent form~Exclusion Criteria:~* IPV or OPV booster dose after the age of 12 years~* Positive for HIV, Hepatitis B or Hepatitis C~* Known or suspected allergy against any of the vaccine components~* History of unusual or severe reactions to any previous vaccination~* Known or suspected disease or use of medication that may influence the immune system~* Known or suspected immune deficiency~* Systemic treatment with corticosteroids within one month before screening~* Administration of plasma (including immunoglobulins) or blood products three months prior to the study~* Blood donation within one month before screening~* Any vaccination within three months before screening and during the study until the last visit~* History of any neurological disorder including epilepsy or febrile seizures~* Evidence of excessive alcohol use or drug use~* Any infectious disease at the time of screening and/or inclusion~* Participation in another clinical trial within three months before screening~* Abnormal pre-treatment laboratory parameters which are clinically relevant according to the investigator~* Bleeding disorders or the usage of anticoagulants

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Sabin-IPV (Type: EXPERIMENTAL): Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, and 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose
- Adjuvanted Sabin-IPV (Type: EXPERIMENTAL): Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, and 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose, adjuvanted with 0.5 mg aluminium hydroxide
- IPV (Type: ACTIVE_COMPARATOR): Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose

Based on this trial design, predict the completion outcome and termination type (if applicable).